Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up

Why It Matters

The erosion of Elevidys’ commercial momentum jeopardizes Sarepta’s revenue base and signals a potential shift in the DMD treatment landscape toward emerging gene‑therapy rivals.

Key Takeaways

• Elevidys sales fell 80% after 2025 safety incidents
• Competitors RGX‑202 and SGT‑003 target same AAV vector
• Investors doubt efficacy despite three‑year data claim
• Patient advocacy pressure intensifies over data transparency
• Sarepta aims $500M 2026 sales floor, unlikely to meet

Pulse Analysis

The Elevidys controversy underscores a broader challenge for pioneering gene‑therapy firms: balancing breakthrough science with rigorous safety oversight. While Sarepta touts a four‑point NSAA improvement over three years, the lack of granular data and the specter of AAV‑related fatalities have sown doubt among investors and clinicians alike. This skepticism is amplified by a volatile market environment where a single safety signal can trigger an 80% share plunge, forcing the company to re‑evaluate its communication strategy and investor relations approach.

Competing developers are capitalizing on Sarepta’s vulnerability. REGENXBIO’s RGX‑202, slated for a mid‑2026 BLA filing, and Solid’s SGT‑003, which showed early muscle‑health gains, both employ the same AAV9 vector, raising concerns about cross‑immunity and patient eligibility. The emerging pipeline suggests that patients and families may soon have viable alternatives, eroding Elevidys’ monopoly and compelling payers to reassess reimbursement models. As the DMD market matures, the ability to deliver differentiated efficacy data will become a decisive factor for market share.

Sarepta’s response—boosting sales force, launching promotional campaigns, and pledging greater patient engagement—may not suffice if the pipeline stalls. The projected $500 million 2026 sales floor hinges on sustained uptake, yet current run‑rate trends indicate a shortfall. For the biotech, securing a next‑generation product or strategic partnership will be essential to restore confidence and protect long‑term valuation. Stakeholders should monitor regulatory timelines for RGX‑202 and SGT‑003, as well as any forthcoming safety updates from Sarepta, to gauge the future trajectory of DMD therapeutics.